Opinion|Videos|December 18, 2024
Iron Deficiency and Cardiovascular Interventions
Author(s)Orly Vardeny, PharmD, MS
A panelist discusses how the multicenter ferric carboxymaltose trial employed a prospective design to evaluate iron supplementation's impact on heart failure outcomes, strategically selecting hospitalization reduction as the primary end point due to its clinical relevance and statistical power considerations.
Advertisement
Video content above is prompted by the following:
- For the ferric carboxymaltose study “Assessing the Effectiveness of Ferric Carboxymaltose for Treating Iron Deficiency in Heart Failure Patients Along With its Effect on Clinical Parameters,” could you explain the study's prospective, multicenter design, including how patients were allocated and the rationale behind the primary end point?
- What were the most notable clinical outcomes observed in this trial?
- Can you explain why there was a reduction in hospitalizations but no impact on mortality?
- What are the potential clinical implications of intravenous iron supplementation in patients with heart failure?
- What emerging research directions and knowledge gaps are highlighted by these cardiovascular clinical investigations, and how might future studies build upon these foundational findings?
Advertisement
Related to this article
Rebisufligene etisparvovec-hopf (Fayuvi; Ultragenyx) is a 1-time gene therapy that addresses the underlying cause of Sanfilippo syndrome type A.
Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.
Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.
The study’s primary end point of event-free survival demonstrated a 49% reduction in mortality risk between the blinatumomab and control cohorts.
Each additional hour of nightly CPAP use was associated with 13% lower all-cause mortality risk in a French cohort of adults with sleep apnea.
AI-assisted spirometry, imaging biomarkers, and population screening strategies highlighted early detection and prevention as a throughline at the ERS Congress.
Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.
A systematic review finds people with narcolepsy and idiopathic hypersomnia often stay employed but face work impairment and limited workplace support.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First Treatment for Sanfilippo Syndrome Type A
2
Real-World Data: FACT vs Non-FACT CAR T Outcomes Compared
3
No Blood Biomarker Is Ready to Pick Psoriasis Therapy
4
Oral GLP-1s, Medicare Bridge Reshape Obesity Care: Holly Lofton, MD
5